Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

While China Pulls Ahead In Regenerative Medicine Research, Its Loosely Regulated Stem Cell Treatment Centers Raise International Concerns

This article was originally published in PharmAsia News

Executive Summary

BEIJING - China's ascendancy as a world power in regenerative medicine has been marked by a rapid-fire increase in the writing of top-level papers in the field for international scientific publications, but also by the appearance of controversial stem cell centers that sometimes offer treatments that have not been tested in clinical trials

You may also be interested in...



U.S.-based NeoStem Signs Twin Agreements To Provide Stem Cell Treatments To Chinese Hospitals

BEIJING - The New York-headquartered biopharmaceutical firm NeoStem Inc has signed twin agreements to provide a leading-edge stem cell-based orthopedic therapy to two Chinese hospitals

U.S.-based NeoStem Signs Twin Agreements To Provide Stem Cell Treatments To Chinese Hospitals

BEIJING - The New York-headquartered biopharmaceutical firm NeoStem Inc has signed twin agreements to provide a leading-edge stem cell-based orthopedic therapy to two Chinese hospitals

China Emerging As World Power In Stem Cell Research

BEIJING - China is speedily evolving into a global power in terms of stem cell research, with the central government stepping up funding and recruiting scientists worldwide in order to catapult the country into the advance ranks of regenerative medicine, according to four scholars at the University of Toronto

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel